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Effect of HMG-CoA reductase inhibitors on chronic allograft dependent and alloantigen-independent factors [1]. The
rejection. alloantigen-dependent factors include B- and T-cell acti-
Background. Although chronic rejection is the most impor- vation and the effects of a variety of different cytokines
tant cause of late allograft loss, none of the currently available
and growth factors. Alloantigen-independent factors in-immunosuppressive agents successfully target this problem.
clude the deleterious effects of reperfusion injury, hyper-Clinical and laboratory studies suggest that 3-hydroxy-3-methyl-
tension, cytomegalovirus (CMV) infection and hyper-glutaryl co-enzyme A (HMG-CoA) reductase inhibitors (HRIs)
may decrease the incidence of and pathophysiologic factors lipidemia. Once sustaining initial injury, the vascular
leading to chronic rejection. endothelium releases various cytokines and chemoattrac-
Methods. A number of clinical and laboratory investigations tants including platelet-derived growth factor, thrombox-
have been designed to evaluate the effect of HRIs on chronic
ane, platelet activating factor and tumor necrosis factor.rejection.
Circulating monocytes, macrophages, lymphocytes, neu-Results. Clinical trials in heart transplant patients suggest
trophils and natural killer cells are attracted into the areathat HRIs decrease the incidence of chronic rejection in a
manner that may be independent of lipid lowering. Subsequent of injury and subsequently produce various additional
studies in animal transplant models confirm that HRIs reduce injurious cytokines and growth factors. The end product
chronic rejection. In further studies to elucidate the possible of this process of cell migration and the elaboration ofmechanisms of this effect, it has been observed that HRIs have
these cytokines and growth factors is smooth muscle cellan inhibitory effect on an number of lymphoid cell lines and
proliferation and migration into the intima with resultingvascular smooth muscle cells. HRIs may also prevent chronic
initimal thickening, vascular luminal obliteration, tubu-rejection by protecting the endothelium from injury and dys-
function, perhaps by up-regulating nitric oxide synthesis. lar atrophy and a number of glomerular changes that
Conclusions. HRIs may be the first agents to be effective define the histological lesions of chronic rejection [2].
in preventing chronic rejection. Although the mechanism be- Our group and others have recently shown that
hind this protective effect is unclear, it seems likely that HRIs 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)may affect multiple factors that could lead to chronic rejection.
reductase inhibitors (HRIs) decrease the incidence and
progression of transplant coronary vasculopathy in hu-
man heart transplant recipients [3, 4]. Transplant coro-Chronic rejection is the most important cause of long-
nary vasculopathy (TCV) is a term used for the chronic
term allograft loss. This process bears much of the re- rejection analogue in heart transplantation. We have also
sponsibility for the fact that only 20% of cadaveric kid- shown that pravastatin, one of the HRIs, decreases the
neys continue to function at 10 years post-transplant. incidence of acute rejection after human kidney trans-
This allograft attrition rate is virtually unchanged through- plantation [5]. Acute rejection has been considered a
out the transplant experience [1], despite the use of new risk factor for the development of chronic rejection [6].
immunosuppressive medications and a subsequent de- A number of laboratory studies now suggest that HRIs
crease in the incidence of acute rejection episodes. The may affect a number of factors, both alloantigen-depen-
great advances in immunosuppression thus have not sig- dent and alloantigen-independent, in a way that may
nificantly affected the incidence of chronic rejections. lead to a decrease in the incidence of chronic rejection.
The initial injury to the allograft leading to chronic The purpose of this article is to summarize the data
rejection appears to be damage to the vascular endothe- published to date suggesting the beneficial effect of HRIs
in combating chronic rejection.lium mediated by a number of different alloantigen-
CLINICAL TRIALSKey words: pravastatin, simvastatin, nitric oxide, B cell, T cell, trans-
plant coronary vasculopathy. We first reported the antirejection effects of prava-
statin in a prospective randomized trial in heart trans- 1999 by the International Society of Nephrology
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plant recipients [3]. Patients receiving daily pravastatin different with respect to baseline clinical or demographic
therapy (40 mg) had a significantly increased one-year characteristics. The results of this study demonstrate that
survival rate (94% vs. 78%, P 5 0.02) that coincided pravastatin treated patients had decreases in the inci-
with a significant decrease in the incidence of clinically dence of acute rejection episodes (64% vs. 25% in the
severe acute rejection episodes (3 of 47 patients in the control group, P , 0.01) and decreases in the use of
pravastatin-treated group and 14 of 50 patients in the both OKT3 (0.04 course per patient vs. 0.08 course per
control group, P 5 0.005). All patients in this study were patient in the control group, P 5 0.02) and solumedrol
treated with prednisone, azathioprine and cyclosporine (0.33 course per patient vs. 0.88 course per patient in
as their baseline immunosuppressive regimen. There the control group, P 5 0.01). As acute rejection may
were no differences in baseline demographic and clinical be the most significant clinical factor leading to chronic
parameters between groups. This study cohort was also rejection [6], pravastatin may affect the incidence of
followed to assess the effect of pravastatin on the inci- chronic rejection in these patients. Follow-up data are
dence and progression TCV. The total number of pa- currently being collected.
tients found to have TCV by angiography or autopsy
was less in the pravastatin-treated group than the control
group (3 patients in the pravastatin group vs. 10 patients ANIMAL MODELS OF CHRONIC REJECTION
in the control group, P 5 0.05). In a subgroup of 48 A number of studies utilizing animal models of chronic
patients (27 in the pravastatin group and 21 in the control rejection (or, TCV) have been published suggesting that
group), intracoronary ultrasound was performed imme-
HRIs may be helpful in preventing or treating this dis-diately after transplantation and at one-year post-trans-
ease. Mesier et al described a rat heterotopic heart trans-plant. It was noted that the pravastatin treated patients
plant model wherein simvastatin treatment significantlyhad a decrease in the rate of progression of TCV as
reduced the incidence of TCV [7]. This effect was inde-compared with the control group, as evidenced by reduc-
pendent of lipid lowering. In another rat heterotopictions in both the maximal intimal thickness (0.11 mm vs.
heart transplant model, Maggard et al described that23 mm, P 5 0.002) and the intimal index (0.05 vs. 0.10,
pravastatin inhibited the development of transplant cor-P 5 0.03).
onary vasculopathy. They also noted an inhibition of theSimilar findings were also recently reported with sim-
synthesis and subsequent degradation of extracellularvastatin, another HRI. Wenke et al reported results of
matrix proteins as well as a decrease in the number ofa four-year prospective randomized study of simvastatin
graft-infiltrating macrophages in the pravastatin-treatedin heart transplant recipients [4]. In the course of four
animals [8]. In a rat orthotopic liver transplant model,years after transplantation, the simvastatin treated group
had significantly better long-term survival (88.6% vs. Kakkis et al showed that pravastatin therapy improved
70.3%, P 5 0.05), and a lower incidence of TCV in the rat survival and decreased the incidence of chronic rejec-
coronary angiographic findings (16.6% vs. 42.3%, P 5 tion [9]. Finally, in a rat model of chronic rejection utiliz-
0.045). The incidence of acute allograft rejections did ing orthotopic femoral artery allografts, we showed that
not differ between the two groups, although there was rats pretreated with pravastatin and cyclosporine three
a trend toward a lower number of serious rejections in days prior to engraftment demonstrated a reduction in
the simvastatin group (2.8% vs. 13.5%, P 5 0.1). In the development of chronic rejection as measured by a
addition, intracoronary ultrasound performed after four decrease in intimal proliferation as compared with con-
years in a subgroup of 27 patients (simvastatin, N 5 10; trol animals treated with cyclosporine alone [10].
control, N 5 17) showed a lower intimal index, that is,
a measure of intimal area (13.8 6 7.1% vs. 27.9 6 12.1%,
P 5 0.04). In both heart transplant trials, although the EFFECT OF HMG-COA REDUCTASE
HRIs were successful in decreasing lipid levels there INHIBITORS ON VARIOUS CELL LINES
was no clear correlation between lipid levels and the T lymphocytes
incidence of acute or chronic rejection.
We have shown that pravastatin and cyclosporine areWe also noted an apparent immunomodulatory effect
synergistic in their ability to decrease cytotoxic T lym-of pravastatin in kidney transplant recipients. In a pro-
phocyte (CTL) activity [11]. In a one-way mixed lympho-spective, randomized, open-labeled pilot study, we stud-
cyte reaction, we demonstrated that the combination ofied the effects of early pravastatin use after cadaveric
pravastatin and cyclosporine decreases CTL cytotoxicitykidney transplantation [5]. Forty-eight patients were ran-
from 41.4% kill of target cells to 20.3% kill (P , 0.01).domized to a group taking pravastatin at 20 mg/day or
Cutts et al and others have shown that HRIs decreaseto a control group. All patients in this study were main-
the proliferation of mitogen-stimulated T-lymphocytestained on a double immunosuppressive regimen with
prednisone and cyclosporine. The two groups were not in vitro [12].
Katznelson: HMG-CoA reductase inhibitors and chronic rejection S-119
B lymphocytes post-translational processing of newly synthesized p21
ras protein, probably by inhibiting its farnesylation. InB-cell activity also seems to be inhibited by HRIs. In
a parallel study, we have shown that pravastatin inhibitstheir rat heteroptopic heart transplant model, Maggard
ras activity [19], again probably by decreasing the pro-et al demonstrate that IgG allo-antibody production is
duction of the farnesyl moiety (a metabolite of the cho-diminished in the same pravastatin-treated rats that also
lesterol synthesis pathway), thus subsequently decreas-demonstrate an inhibition of transplant vasculopathy [8].
ing the production of farnesylated ras, its activatableThis is suggestive of an inhibitory effect of HRIs on B
form. This was associated with a decrease in VSMCcell activity. In addition, Rudich et al have shown that
proliferation.both pravastatin and simvastatin diminishes B-lymphocyte
activation [13].
EFFECT OF HRIs ON LIPID LEVELS
Monocytes AND ENDOTHELIAL CELL RESPONSE—
HMG-CoA reductase inhibitors also affect mono- AN IMPACT ON CHRONIC REJECTION?
cytes. Kreuzer, Bader and Jahn have demonstrated that Hyperlipidemia is a prevalent complication of solid
pravastatin decreases monocyte chemotaxis [14]. In addi- organ transplantation affecting up to 80% of recipients
tion, fluvastatin has been shown to decrease monocyte [20]. HRIs have been demonstrated to be safe and effi-
expression of LFA-1 and ICAM-1 [15], thus decreasing cacious in the treatment of post-transplant hyperlipid-
their ability to interact with endothelial cells and other emia [20]. Hyperlipidemia may be an independent risk
lymphoid cell types. This effect was reversed by adding factor for the development of chronic rejection. Some,
mevalonate back to the experimental system. Lovastatin but not all, authors have correlated post-transplant hy-
decreases monocyte expression of the CD11b/CD18 perlipidemia with the development of TCV after heart
complex [16], thus also decreasing their ability to adhere transplantation [21]. Hyperlipidemia may also be a risk
to and inflict injury on vascular endothelial cells. factor for the development of chronic rejection after
kidney transplantation [22]. The pathophysiology of any
Natural killer cells
effect of elevated lipid levels on the development of
Some of the earliest studies were performed by Cutts chronic rejection is unclear. Some authors have sug-
and Bankhurst, who showed that HRIs decrease natural gested that elevated levels of oxidized low density lipo-
killer cell (NKC) cytotoxicity in vitro [17]. The addition protein (LDL) in the allograft may lead to endothelial
of mevalonate back to the culture medium restored NKC cell injury and subsequently TCV. Although lipid levels
cytotoxicity, suggesting that it was truly a decreased pro- were lower in the heart transplant patients treated with
duction of a downstream metabolite of the cholesterol pravastatin [3, 5] and simvastatin [4] discussed earlier in
synthesis pathway that was responsible for the inhibition this article, there was no direct correlation between the
of NKC cytotoxicity. In this assay, cellular activity was absolute lipid levels or changes in lipid levels and the
also restored after the introduction of small amounts of development of either acute or chronic rejection. Thus,
interleukin-2 to the culture medium. In an ex vivo study, although control of post-transplant hyperlipidemia may
we demonstrated that NKC cytotoxicity was inhibited by be important with respect to helping address the problem
more than 50% in heart and kidney transplant patients of the high incidence of cardiovascular ischemic events
taking pravastatin [3, 5]. In these studies, there was no in the post-transplant setting, conclusive evidence sug-
direct correlation between the degree of NKC inhibition gesting that lowering lipid levels with HRIs helps to
and the occurrence of acute rejection episodes in any prevent or treat chronic rejection has not yet been ob-
given patient. The inhibition of NKC activity in this study tained. In fact, in one rat model of chronic rejection,
was not associated with an increased risk of infectious simvastatin was successful in protecting against the de-
episodes or de novo malignancies. velopment of chronic rejection without any effect on
lipid levels [7].
Vascular smooth muscle cells As previously mentioned, the response of the allograft
As mentioned earlier in this article, vascular smooth endothelium to injury is the initial process in the develop-
muscle cell (VSMC) proliferation is a vital pathophysio- ment of chronic rejection. It has been hypothesized that
logical event in the development of chronic rejection. HRIs may protect the endothelium by stabilizing these
Negre-Aminou et al studied the antiproliferative effects cells even in the presence of injurious substances or
of all of the clinically available HRIs on human VSMCs events. Although this argument was mostly conjecture
[18], and found that all of these agents have antiprolifera- until recently in the transplant literature, there is some
tive activity, though each to a different degree. Of the new evidence suggesting that HRIs may protect the allo-
agents tested, cerivastatin was the most potent antiprolif- graft vascular endothelium by interactions with nitric
oxide (NO). NO has a number of properties critical toerative drug. Simvastatin was also noted to inhibit the
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